| Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma |
NCT04047680: eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs |
|
|
| Completed | N/A | 441 | RoW | Sofosbuvir / Velpatasvir Oral Tablet, Epclusa, Sofosbuvir and Ledipasvir, Harvoni, Sofosbuvir Tablets, Solvadi, Ombitasvir/paritaprevir/ritonavir, Viekirax/exviera, Elbasvir / Grazoprevir Oral Tablet, Zepatier, Glecaprevir and Pibrentasvir, Maviret | National Taiwan University Hospital | Hepatitis C, Renal Disease, Viral Hepatitis C | 12/18 | 06/19 | | |
| Approved for marketing | N/A | | Europe | glecaprevir, ABT-493, pibrentasvir, ABT-530 | AbbVie | Hepatitis C Virus Infection | | | | |
NCT03303599: Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6 |
|
|
| Completed | N/A | 2118 | Europe, RoW | | AbbVie | Hepatitis C | 01/20 | 01/20 | | |
EVEREST, NCT03868163: Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation |
|
|
| Completed | N/A | 161 | RoW | | AbbVie | Chronic Hepatitis C (CHC) | 09/20 | 09/20 | | |
NCT03341871: Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6 |
|
|
| Completed | N/A | 1095 | Japan | | AbbVie | Hepatitis C Virus (HCV) | 09/20 | 09/20 | | |
NCT04352309: Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis |
|
|
| Completed | N/A | 99 | RoW | | AbbVie | Hepatitis C Virus (HCV) | 06/21 | 06/21 | | |
DETI-2, NCT04189627: A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation |
|
|
| Completed | N/A | 99 | RoW | | AbbVie | Hepatitis C Virus (HCV) | 06/21 | 06/21 | | |
NCT03941821: Glecaprevir/Pibrentasvir Real-world Study in China |
|
|
| Unknown status | N/A | 800 | NA | Glecaprevir/Pibrentasvir, Mavyret | Tongji Hospital | Chronic Hepatitis c | 06/21 | 06/22 | | |
TEMPO, NCT03492112: A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams |
|
|
| Completed | N/A | 101 | RoW | HCV RNA Point of Care, GeneXpert System, Sofosbuvir/velpatasvir, Epclusa, Glecaprevir/pibrentasvir, Maviret | Kirby Institute | Hepatitis C | 11/21 | 11/21 | | |
SCALE-C, NCT03776760: Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination |
|
|
| Recruiting | N/A | 600 | RoW | Fingerstick GeneXpert HCV RNA quantitative assay, sofosbuvir/velpatesvir, Epclusa, glecaprevir/pibrentasvir, Maviret | Kirby Institute, South Australian Health and Medical Research Institute, Flinders University | Hepatitis C, Hepatitis, Liver Diseases, Hepatitis, Viral, Human, RNA Virus Infections, Digestive System Diseases | 08/22 | 08/22 | | |
CHOICE, NCT04577482: Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response |
|
|
| Completed | N/A | 42 | RoW | | AbbVie | Hepatitis C Virus (HCV) | 09/22 | 09/22 | | |
TOPIC, NCT03981211: Treatment of HOsPitalised Inpatients for Hepatitis C (): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs |
|
|
| Recruiting | N/A | 60 | RoW | Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet, Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet | Kirby Institute | Hepatitis C, Liver Inflammation, Liver Cirrhoses | 02/25 | 02/25 | | |
| Completed | N/A | 17 | US | Suboxone, Buprenorphine Naloxone, Truvada, Pre-Exposure Prophylaxis (PrEP), Mavyret, Hepatitis C treatment | Duke University, Center for AIDS Research (CFAR), National Institute of Allergy and Infectious Diseases (NIAID) | Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C | 03/23 | 03/23 | | |
Maviret PMS, NCT03740230: An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs |
|
|
| Completed | N/A | 3134 | RoW | | AbbVie | Hepatitis C | 07/23 | 07/23 | | |
NeoVie, NCT04366973: A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers |
|
|
| Completed | N/A | 95 | Europe | | AbbVie | Hepatitis C Virus (HCV) | 12/23 | 12/23 | | |
NCT06367465: Feasibility and Acceptability of HCV Treatment in Pregnancy |
|
|
| Recruiting | N/A | 50 | US | Glecaprevir-pibrentasvir | Washington University School of Medicine | Hepatitis C, Pregnancy Complications | 02/26 | 02/26 | | |
NCT04214028: A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus |
|
|
| Completed | N/A | 50 | Japan | | AbbVie | Hepatitis C Virus (HCV) | 08/24 | 08/24 | | |
